Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

BURLINGTON, N.C. , June 12, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, previously announced the following record and distribution dates for its spin-off of Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp ("Fortrea"): The record date will be 5:00 p.m.

LABCORP ANNOUNCES ADDITIONAL INFORMATION IN CONNECTION WITH ITS SPIN-OFF OF FORTREA

Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.

LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure

BURLINGTON, N.C. , June 9, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced the following record and distribution dates for the spin-off of Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp ("Fortrea"): The record date will be 5 p.m.

Labcorp Announces Information in Connection with its Spin-off of Fortrea

BURLINGTON, N.C. , June 8, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced that Fortrea Holdings Inc., a wholly owned subsidiary of Labcorp ("Fortrea"), has launched an offering of senior secured notes due 2030 (the "Notes"), subject to market conditions and other customary factors, in connection with the previously announced spinoff of Fortrea into a separate publicly traded company (the "Spinoff").

Labcorp Announces Launch of Fortrea's Notes Offering in Connection with Anticipated Spinoff

After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.

LabCorp (LH) Provides Update on Planned Spinoff of Fortrea

Health system executive brings three decades of medical enterprise experience to Labcorp BURLINGTON, N.C. , June 7, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced the appointment of Dr. Paul Rothman to its Board of Directors as an independent member.

Labcorp Appoints Dr. Paul Rothman to Board of Directors

BURLINGTON, N.C. , June 5, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced Fortrea, the new company to be formed by the planned spin-off of Labcorp's Clinical Development and Commercialization Services business, will host its inaugural Investor Day on Tuesday, June 6, 2023, in New York City at 9 a.m.

Labcorp's Planned Spin-off, Fortrea, to Host 2023 Investor Day

The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.

LabCorp (LH) Expands Precision Oncology With Biopsy Test

Liquid biopsy test for cancer patients enables oncologists to identify targeted therapies and improve care BURLINGTON, N.C. , May 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, has launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted therapy selection for patients with advanced or metastatic solid tumors.

Labcorp Plasma Focus™ Liquid Biopsy Test Now Available

LabCorp (LH) reported earnings 30 days ago. What's next for the stock?

Why Is LabCorp (LH) Down 2.7% Since Last Earnings Report?

ZURICH-SCHLIEREN, Switzerland--(BUSINESS WIRE)--Proteomedix, a Swiss diagnostics company committed to advancing prostate cancer care, announced today that it entered into an agreement for Labcorp, a leading global life sciences company, to be the only laboratory to develop and commercialize the Proclarix® Prostate Specific Antigen (PSA) test in the U.S.. Proclarix is performed using the same blood sample as a PSA test, and is designed to help determine the risk of clinically significant prostat.

Proteomedix Agrees to Issue Labcorp Exclusive License for Proclarix® Blood Test to Detect Prostate Cancer

LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.

LabCorp (LH) Expands Laboratory Relationship With New Pact

Amgen

Bristol-Myers

Cigna

Centene

Gilead Sciences

Organon & Co

Pfizer

Viatris

The stocks our screen found are cheap, relative to highfliers like Eli Lilly, and many are cheap for a reason.

9 Cheap Healthcare Stocks to Consider

Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.

LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays

Patients and Providers in Oregon Region Will Gain Broader Access to Labcorp's Diagnostic Testing and Laboratory Services Labcorp and Providence Health & Services – Oregon (Providence Oregon) have entered into an agreement for Labcorp to acquire select assets of Providence Oregon's outreach laboratory business Providence Oregon will maintain ownership of certain anatomic pathology and genomics outreach testing and hospital laboratories located in Oregon Transaction builds on more than 20-year relationship between the Providence family of organizations and Labcorp BURLINGTON, N.C. , May 16, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced it entered into an agreement with Providence to expand the longstanding strategic relationship between the two organizations.

Labcorp and Providence Expand Strategic Laboratory Relationship

BURLINGTON, N.C. , May 4, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced that its Annual Meeting of Shareholders will be webcast live on May 11 at 9:00 a.m.

LABCORP TO WEBCAST ITS ANNUAL MEETING OF SHAREHOLDERS

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a leading manufacturer of genetic medicines, today announced a gene therapy development and manufacturing collaboration with Labcorp (NYSE: LH), a leading global life sciences company. As a result of this strategic collaboration, gene therapy clients across the industry will gain access to manufacturing capabilities, drug development services, and coordinated scientific expertise, creating greater accessibility to services for adeno-associated v.

Forge Biologics and Labcorp Announce Strategic AAV Gene Therapy Development and Manufacturing Collaboration

Physicians and Patients Will Gain Access to Enhanced Laboratory Services and Advanced Diagnostic Testing Labcorp will acquire select assets of Jefferson's outreach laboratory services Jefferson will continue to own and operate their existing hospital labs for outpatient and inpatient services BURLINGTON, N.C. , May 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson), the largest health system serving the greater Philadelphia area and Southern New Jersey.

LABCORP AND JEFFERSON HEALTH ANNOUNCE STRATEGIC LABORATORY RELATIONSHIP

Enzo Biochem

NEW YORK , May 2, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Enzo Biochem, Inc. ("Enzo Biochem" or the "Company") (NYSE: ENZ) in connection with its acquisition by Laboratory Corporation of America Holdings (NYSE: LH) ("Labcorp").  The transaction value is approximately $146 million.

SHAREHOLDER ALERT: Weiss Law Investigates Enzo Biochem, Inc.

Laboratory Corporation of America Holdings (LH) Q1 2023 Earnings Call Transcript.

Laboratory Corporation of America Holdings (LH) Q1 2023 Earnings Call Transcript

The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.

LabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline

While the top- and bottom-line numbers for LabCorp (LH) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, LabCorp (LH) Q1 Earnings: A Look at Key Metrics

LabCorp (LH) came out with quarterly earnings of $3.82 per share, missing the Zacks Consensus Estimate of $3.99 per share. This compares to earnings of $6.11 per share a year ago.

LabCorp (LH) Misses Q1 Earnings Estimates

Company Updates Full-Year Guidance First quarter Base Business revenue grew 10%, while total revenue and earnings were down due to COVID-19 Testing Revenue: Q1 of $3.8 billion versus $3.9 billion last year Diluted EPS: Q1 of $2.39 versus $5.23 last year Adjusted EPS: Q1 of $3.82 versus $6.11 last year Free Cash Flow: Q1 of $27 million versus $239 million last year Planned spin of Clinical Development business remains on schedule for mid-2023 Full-Year 2023 Guidance: Adjusted EPS narrowed to $16.25 to $17.75 with midpoint unchanged and Free Cash Flow remains at $1.0 billion to $1.2 billion BURLINGTON, N.C. , April 25, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the first quarter ended March 31, 2023, and updated full-year guidance.

News for Labcorp Holdings Inc Stock (LH)